Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Impaired carbon monoxide diffusing capacity as a marker of limited systemic sclerosis.

Trad S, Huong du LT, Frances C, Wechsler B, Cacoub P, Costedoat N, Haroche J, Piette JC, Hanslik T, Amoura Z.

Eur J Intern Med. 2011 Dec;22(6):e80-6. doi: 10.1016/j.ejim.2011.05.007. Epub 2011 Jun 12.

PMID:
22075318
2.

High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.

Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, Mouthon L, Guillevin L, Meyer O, Ekindjian OG, Weber S, Kahan A.

Arthritis Rheum. 2008 Jan;58(1):284-91. doi: 10.1002/art.23187.

3.

[Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study].

Liu QX, Zheng JP, Xie YQ, Guan WJ, Jiang CY, An JY, Yu XX, Liu WT, Gao Y.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Jul;36(7):510-5. Chinese.

PMID:
24262087
4.
5.

Different diffusing capacity of the lung for carbon monoxide as predictors of respiratory morbidity.

Cerfolio RJ, Bryant AS.

Ann Thorac Surg. 2009 Aug;88(2):405-10; discussion 410-1. doi: 10.1016/j.athoracsur.2009.04.015.

PMID:
19632384
6.

Isolated diffusing capacity reduction in systemic sclerosis.

Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr.

Arthritis Rheum. 1992 Jul;35(7):765-70.

PMID:
1622414
7.

Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.

Colaci M, Giuggioli D, Sebastiani M, Manfredi A, Lumetti F, Luppi F, Cerri S, Ferri C.

Reumatismo. 2015 Dec 23;67(4):149-55. doi: 10.4081/reumatismo.2015.837.

8.

Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.

Guarnieri G, Zanatta E, Mason P, Scarpa MC, Pigatto E, Maestrelli P, Cozzi F.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S80-6. Epub 2015 Apr 16.

PMID:
25897784
9.

Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension.

Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M.

J Heart Lung Transplant. 2010 Feb;29(2):181-7. doi: 10.1016/j.healun.2009.07.005. Epub 2009 Sep 26.

PMID:
19783169
10.

Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide.

Pernot J, Puzenat E, Magy-Bertrand N, Manzoni P, Gondouin A, Bourdin H, Simon-Rigaud ML, Regnard J, Degano B.

Respiration. 2012;84(6):461-8. doi: 10.1159/000335473. Epub 2012 Jan 31.

12.

KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.

Fathi M, Barbasso Helmers S, Lundberg IE.

J Intern Med. 2012 Jun;271(6):589-97. doi: 10.1111/j.1365-2796.2011.02459.x. Epub 2011 Oct 31.

13.

Increase of pulmonary diffusing capacity in systemic sclerosis.

Dujić Z, Eterović D, Tocilj J, Andjelinović D.

Br J Rheumatol. 1994 May;33(5):437-41.

PMID:
8173847
14.

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.

Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group.

Arthritis Rheum. 2005 Feb;52(2):592-600.

15.

Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease.

Someya F, Mugii N, Hasegawa M, Yahata T, Nakagawa T.

Respir Care. 2014 Jan;59(1):75-80. doi: 10.4187/respcare.02452. Epub 2013 Jun 13.

16.

Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis.

Sivova N, Launay D, Wémeau-Stervinou L, De Groote P, Remy-Jardin M, Denis G, Lambert M, Lamblin N, Morell-Dubois S, Fertin M, Lefevre G, Sobanski V, Le Rouzic O, Hatron PY, Wallaert B, Hachulla E, Perez T.

PLoS One. 2013 Oct 18;8(10):e78001. doi: 10.1371/journal.pone.0078001. eCollection 2013.

17.

Pulmonary diffusion capacity in patients with systemic lupus erythematosus.

Nakano M, Hasegawa H, Takada T, Ito S, Muramatsu Y, Satoh M, Suzuki E, Gejyo F.

Respirology. 2002 Mar;7(1):45-9.

PMID:
11896900
18.

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU.

Arthritis Rheumatol. 2017 Aug;69(8):1670-1678. doi: 10.1002/art.40130. Epub 2017 Jul 18.

PMID:
28426895
19.

[Lung involvement in systemic sclerosis].

Quadrelli S, Ciallella L, Catalán Pellet AC, Molinari L, Salvado A, Auad C, Spina JC.

Medicina (B Aires). 2007;67(5):429-35. Spanish.

PMID:
18051224
20.

Diffusing Pulmonary Capacity Measured During Effort: A Possible Early Marker of Pulmonary Involvement In Systemic Sclerosis.

Legnani D, Rizzi M, Sarzi-Puttini P, Cristiano A, La Spina T, Frassanito F, Airoldi A, Atzeni F.

Isr Med Assoc J. 2015 Dec;17(12):739-43.

Supplemental Content

Support Center